NASH Biomarker

Explore the importance of biomarkers in the diagnosis, management, and treatment of Non-Alcoholic Steatohepatitis (NASH). Stay informed about the latest research and advancements.

Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice

Authors: Ilagan-Ying Y, Ilagan-Ying B et al
Published in Current Gastroenterology Reports (2023)
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease, affecting a staggering 30% of the global population.
Read MoreScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice

An exploration of MAFLD’s clinical utility

Authors: Ramírez-Mejía MM, Xingshun Q, Abenavoli L et al
Published in Annals of Hepatology (July 2023)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utility

NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Authors: Loomba R, Huang DQ, Sanyal AJ et al.
Published in Gut (March 2023)
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Adipose tissue insulin resistance and fibrosis stage in NASH

Authors: Kalavalapalli S, Leiva EG, Lomonaco R et al.
Published in Journal of Clinical Endocrinology and Metabolism (April 2023)
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
Read MoreAdipose tissue insulin resistance and fibrosis stage in NASH

Hepatic Macrophages in NAFLD: A Novel Therapeutic Target?

Authors: Vonderlin J, Chavakis T, Sieweke M et al.
Published in Cellular and Molecular Gastroenterology and Hepatology (March 2023)
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Read MoreHepatic Macrophages in NAFLD: A Novel Therapeutic Target?

Biomarker Qualification for NAFLD and NASH: Insights from the LITMUS Consortium

Authors: Rasmussen DGK, Anstee QM, Torstenson R et al.
Published in Journal of Hepatology (April 2023)
Interventional trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, are often limited by patient heterogeneity and, hence, response variability.
Read MoreBiomarker Qualification for NAFLD and NASH: Insights from the LITMUS Consortium

The “Perfect” NASH Biomarker: An Unrealistic Pursuit?

Authors: Sebastiani G
Published in Lancet Gastroenterol Hepatol 2023
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts and settings. FIB-4, a cost-effective marker, can be supplemented by complex multimarkers for NASH therapeutic trials. Embracing diagnostic imperfections is crucial for flexible biomarker algorithms.
Read MoreThe “Perfect” NASH Biomarker: An Unrealistic Pursuit?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES